Cerebrolysin Peptide
A peptide preparation made from pig brain, used in clinics across half the world. A 2023 Cochrane review found no mortality benefit and a 2.39 relative risk of serious adverse events. We are leading with that on purpose.
Choose your pack
For research use only. Not for human or veterinary use.
What Cerebrolysin Peptide is
The plain-language version, first.
Not a molecule. A processed extract of pig brain tissue, in clinical use for decades.
Cerebrolysin is not a peptide but a preparation derived from purified porcine brain protein, which mass spectrometry has characterised as 14,635 distinct peptides originating from 1,643 different porcine proteins. A 2023 Cochrane systematic review pooling seven randomised controlled trials in 1,773 acute ischaemic stroke patients reported more serious adverse events in the treated group than in placebo.
Let's do the composition first, because most pages never get to it.
Cerebrolysin is not a peptide in the singular. It is an enzymatic digest of pig brain proteins, a soup of fragments, standardised by process rather than by structure.
No sequence. No molecular weight. A manufacturing method with a trademark on it.
It has been in clinical use across Russia, parts of Europe and Asia for decades, mostly around stroke and neurological conditions, which gives it something almost nothing else here has: a large human record.
And a large human record means somebody eventually audits it properly.
Somebody did. In 2023. It is the most important document about this product and it is three paragraphs down.
What is Cerebrolysin?
Mechanism studied, not outcome promised.
From 1,643 distinct porcine proteins, per mass spectrometry characterisation. There is no single active molecule to attribute an effect to.
For a defined peptide, purity answers is this the right molecule. For a biological extract it answers a much narrower question.
You cannot write a receptor story for a mixture, and this is a mixture.
The proposed story is that small brain-derived peptide fragments mimic the brain's own growth and maintenance factors.
As a hypothesis it is not crazy. Brains do run on peptide signals.
But a digest contains thousands of fragments, and a mechanism attributed to a soup is a mechanism attributed to nothing in particular.
Which fragment does what, at what concentration, varying how much between batches: these questions do not have published answers, because the product is defined by its process.
Here's the honest part, and for once it is not about missing data.
The data exists. It is the audit of it that hurts, and that is the next section's job.
The research so far for Cerebrolysin Peptide
Where the evidence is thin, we say so.
Decades of clinical use and licensure in a number of countries across Eastern Europe and Asia, for stroke, dementia and traumatic brain injury.
A 2023 Cochrane review finding no mortality benefit and a doubled rate of non-fatal serious adverse events. No FDA or EMA approval, ever.
The 2023 Cochrane review pooled 7 randomised controlled trials and 1,773 patients in acute ischaemic stroke. Mortality relative risk 0.96, meaning no benefit. Non-fatal serious adverse events relative risk 2.39, concentrated at the standard dose. More serious adverse events on treatment than on placebo, from the highest tier of evidence synthesis available.
The Cochrane review is the file. Read this section before any other page about it.
In 2023 Cochrane, the closest thing evidence-based medicine has to a supreme court, reviewed the trials.
The findings, plainly: no reduction in deaths, and a relative risk of 2.39 for serious adverse events. More than double.
That is not an absence of evidence. That is evidence, pointed the wrong way.
Decades of clinical use generated enough trials to review, and the review found the benefit missing and a safety signal present. Both halves of that sentence matter.
It remains in clinical use in many countries regardless, which says more about regulatory inertia than about the data.
We will sell you the vial and we will also hand you the Cochrane number, because a store that only shows you one of those two things is not a store you should trust.
Cerebrolysin vial sizes and current Canadian stock are listed below.
Cerebrolysin Peptide specs
The chemistry, exactly as released.
Who studies Cerebrolysin Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Stroke medicine
Acute ischaemic stroke is where the randomised evidence sits, and where the Cochrane review drew its seven trials and 1,773 patients from.
Neurodegeneration research
Dementia and traumatic brain injury are the other indications it is licensed for in the markets that license it.
Analytical chemistry
The mass spectrometry work that identified 14,635 peptides from 1,643 porcine proteins is a study of the preparation itself rather than of its effects.
Evidence reviewers
It is a case study in what happens when a long-licensed biological finally gets a systematic review of its randomised data.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Cerebrolysin Peptide backstory
How it got here.
Cerebrolysin has been produced since the mid twentieth century and is one of the older biological preparations still in clinical use anywhere. It is manufactured by enzymatic breakdown of purified porcine brain protein into a mixture of low molecular weight peptides and amino acids.
It is licensed in a number of countries across Eastern Europe, Asia and elsewhere, and has been prescribed for stroke, dementia and traumatic brain injury for decades in those markets. It has never been approved by the FDA or the EMA.
The trials that would have supported those applications were largely run in the markets where it was already licensed, and the pooled analyses of them are what the 2023 Cochrane review examined.
- 1
A mid-century preparation
Made by enzymatic breakdown of purified porcine brain protein into low molecular weight peptides and free amino acids. One of the older biologicals still in clinical use.
- 2
Licensed, in some places
Approved and prescribed for decades across parts of Eastern Europe and Asia for stroke, dementia and traumatic brain injury. Never approved by FDA or EMA.
- 3
Cochrane, 2023
Seven randomised trials, 1,773 patients pooled. No mortality benefit, and a relative risk of 2.39 for non-fatal serious adverse events.
Buying Cerebrolysin Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
This one is not a defined peptide
It is a porcine brain-derived mixture. Any purity number on a biological extract answers a narrower question than the same number on a defined molecule, and we would rather say that plainly than let a figure imply more than it can.
Read the Cochrane review
Seven randomised trials, 1,773 patients, no mortality benefit and a relative risk of 2.39 for non-fatal serious adverse events. If you are evaluating this compound, that is the document.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Once it lands, fridge. That is the whole ask.
Stuff people ask about Cerebrolysin Peptide
If your question is not here, email us. Real human answers.
Not in the sense every other product on this site is. It is a preparation derived from purified porcine brain protein. Mass spectrometry characterisation identified 14,635 distinct peptides originating from 1,643 different porcine proteins. There is no single sequence, no molar mass and no CAS number for one active molecule, because there is not one.
The 2023 Cochrane systematic review in acute ischaemic stroke pooled 7 randomised controlled trials with 1,773 participants. All-cause mortality showed a relative risk of 0.96, meaning no benefit. Non-fatal serious adverse events showed a relative risk of 2.39, more than double the placebo rate, and the signal was concentrated at the standard dose.
Yes, in a number of countries, largely across Eastern Europe and Asia, where it has been licensed and prescribed for stroke, dementia and traumatic brain injury for decades. It has never been approved by the FDA or the EMA.
Not in a way that means much, and we would rather be straight about that. A purity figure on a fifteen residue peptide tells you the vial contains that molecule and little else. On a mixture of thousands of peptides it describes a much narrower property. Same number, different question.
Because it is a biological extract rather than a synthesised molecule. It is produced by enzymatic breakdown of purified porcine brain protein, and the output of that process is a mixture whose exact composition depends on the input material and the process conditions rather than on a defined synthesis route.
Because it is the single most informative document about this compound and you can find it in a minute. A systematic review reporting a harm signal alongside no efficacy signal is the thing a buyer most needs to know, and we would rather be the ones who told you.
Good pairing options with Cerebrolysin Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Cerebrolysin Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Seven residues that shut a potassium channel called TREK-1. One laboratory, one paper, and a number so striking that the right response is to wait for somebody else to see it too.
The first peptide hormone anyone ever built by hand instead of grinding out of a gland. That synthesis won the 1955 Nobel, and two residues separate it from vasopressin, a completely different hormone.
Order Cerebrolysin Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Cerebrolysin Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for Cerebrolysin Peptide
Other names for the same compound.